Related Experiment Video
Updated: Feb 12, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Novel oral anticoagulants in chronic kidney disease: ready for prime time?
Justin Ashley1,2, Manish M Sood1,2
1The Ottawa Hospital, University of Ottawa.
Insights
Novel oral anticoagulants (NOACs) show promise for patients with chronic kidney disease (CKD), offering comparable or superior efficacy and safety to Vitamin K Antagonists (VKAs) for preventing blood clots and stroke.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Patients with chronic kidney disease (CKD) face heightened risks of atrial fibrillation, stroke, and bleeding.
- Novel oral anticoagulants (NOACs) are emerging as alternatives to Vitamin K Antagonists (VKAs) for preventing venous thromboembolism (VTE) and stroke in atrial fibrillation.
Purpose of the Study:
- To review current literature on the efficacy and safety of NOACs in patients with CKD.
- To address the underdeveloped understanding of NOACs within the context of CKD.
Main Methods:
- Analysis of post hoc data from major NOAC trials.
- Inclusion of meta-analyses and postmarketing surveillance studies focusing on moderate kidney disease.
- Synthesis of recent literature on NOACs in CKD patients.
Main Results:
- NOACs demonstrate equivalent or superior efficacy and safety compared to VKAs in patients with moderate CKD.
- Studies indicate NOACs are well-tolerated and effective for managing VTE and atrial fibrillation.
- Limitations include small sample sizes and a lack of direct comparative studies between different NOACs.
Conclusions:
- NOACs represent a viable therapeutic option for VTE and atrial fibrillation management in CKD patients.
- Further research is needed to determine the optimal NOAC for specific clinical scenarios.
- Continued investigation into NOACs in CKD is crucial for refining treatment strategies.
Purpose Of Review:
Patients with chronic kidney disease (CKD) are at increased risk of atrial fibrillation, stroke, and bleeding posing unique clinical challenges. Novel oral anticoagulants (NOACs) including dabigatran, rivaroxaban, and apixaban have become recognized as alternative therapy to Vitamin K Antagonists (VKA) regarding the prevention of venous thromboembolism (VTE) and reduce the risk of stroke in atrial fibrillation. However, the understanding of NOACs in CKD is still underdeveloped. This review summarizes recent literature on the efficacy and safety of NOACs in patients with CKD.
Recent Findings:
Studies focusing on patients with moderate kidney disease were drawn from post hoc analyses from three major NOAC trials, meta-analyses, and postmarketing surveillance studies. Cumulatively, these studies continue to demonstrate NOACs as equivalent if not superior therapies to VKAs in regards to both efficacy and safety. These studies are limited by small sample sizes as well as a lack of direct comparison between NOACs.
Summary:
The role of NOACs in managing VTE and atrial fibrillation is increasing. Current research suggests that NOACs are at least as efficacious and well tolerated as VKAs. More research is required to elucidate which NOAC is preferable in the clinical setting.
More Related Videos
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
10:51A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
Published on: December 2, 2014
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Chronic Kidney Disease II: Clinical Manifestations
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...